Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

Nature Reviews Genetics

Volumn 17, Issue 5, 2016, Pages 284-299

  Feinberg, Andrew P ^a   Koldobskiy, Michael A ^a   Göndör, Anita ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BIOLOGICAL RESPONSE MODIFIER; DNA METHYLTRANSFERASE 3A; FUMARATE HYDRATASE; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE 1A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; K RAS PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; SMARCB1 PROTEIN; SOMATOMEDIN B; STAT3 PROTEIN; SUCCINATE DEHYDROGENASE; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AGING; BASAL CELL; BECKWITH WIEDEMANN SYNDROME; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STEM CELL; CELL AGING; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL NUCLEUS MEMBRANE; CELL PLASTICITY; CELL PROLIFERATION; CELL RENEWAL; CHROMATIN STRUCTURE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLEAR CELL CARCINOMA; CONCEPTUAL FRAMEWORK; CPG ISLAND; DISEASES; DNA METHYLATION; ECTOPIC EXPRESSION; EMBRYONIC STEM CELL; ENHANCER REGION; ENTROPY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; EPIGENETIC MEDIATOR; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GAIN OF FUNCTION MUTATION; GENOME ANALYSIS; HEPATOBLASTOMA; HETEROCHROMATIN; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; MISSENSE MUTATION; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEAR REPROGRAMMING; OCCUPATIONAL EXPOSURE; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PHENOTYPIC PLASTICITY; PHENOTYPIC VARIATION; PONTINE GLIOMA; PRIORITY JOURNAL; PROGERIA; PROMOTER REGION; PROTEIN PROCESSING; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; T CELL LYMPHOMA; TUMOR GENE; WERNER SYNDROME; WNT SIGNALING PATHWAY; ANIMAL; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; MUTATION; NEOPLASMS; PATHOLOGY; STEM CELL;

ANIMALS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MUTATION; NEOPLASMS; STEM CELLS;

EID: 84961218734     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg.2016.13     Document Type: Review

References (274)

1. Feinberg A. P, Ohlsson R, & Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21-33 (2006).
2. Versteege I, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 394, 203-206 (1998).
3. Lee R. S, et al A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983-2988 (2012).
4. Mack S. C, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 506, 445-450 (2014).
5. Zhang J, et al A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 481, 329-334 (2012).
6. Pugh T. J, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 488, 106-110 (2012).
7. Hovestadt V, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature. 510, 537-541 (2014).
8. Shen H, & Laird P. W. Interplay between the cancer genome and epigenome. Cell. 153, 38-55 (2013).
9. Plass C, et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14, 765-780 (2013).
10. Suva M. L, Riggi N, & Bernstein B. E. Epigenetic reprogramming in cancer. Science. 339, 1567-1570 (2013).
11. Ley T. J, et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010).
12. Yan X. J, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43, 309-315 (2011).
13. Couronne L, Bastard C, & Bernard O. A. TET2 and DNMT3A mutations in human T cell lymphoma. N. Engl. J. Med. 366, 95-96 (2012).
14. Grossmann V, et al. The molecular profile of adult T cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T ALL. Genes Chromosomes Cancer. 52, 410-422 (2013).
15. Ribeiro A. F, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 119, 5824-5831 (2012).
16. Challen G. A, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23-31 (2012).
17. Challen G. A, et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell. 15, 350-364 (2014).
18. Mayle A, et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 125, 629-638 (2015).
19. Celik H, et al. Enforced differentiation of Dnmt3a null bone marrow leads to failure with c Kit mutations driving leukemic transformation. Blood. 125, 619-628 (2015).
20. Quivoron C, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 20, 25-38 (2011).
21. Abdel-Wahab O, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 114, 144-147 (2009).
22. Langemeijer S. M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41, 838-842 (2009).
23. Chou W. C, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 118, 3803-3810 (2011).
24. Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 122, 3616-3627 (2013).
25. Itzykson R, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 121, 2186-2198 (2013).
26. Busque L, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179-1181 (2012).
27. Moran-Crusio K, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20, 11-24 (2011).
28. Madzo J, et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 6, 231-244 (2014).
29. Biegel J. A, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74-79 (1999).
30. Varela I, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469, 539-542 (2011).
31. Jones S, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 330, 228-231 (2010).
32. Wiegand K. C, et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010).
33. Morin R. D, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 476, 298-303 (2011).
34. Pasqualucci L, et al. Analysis of the coding genome of diffuse large B cell lymphoma. Nat. Genet. 43, 830-837 (2011).
35. Beguelin W, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 23, 677-692 (2013).
36. Ernst T, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726 (2010).
37. Nikoloski G, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665-667 (2010).
38. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 333, 1157-1160 (2011).
39. Ntziachristos P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298-301 (2012).
40. Hannum G, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell. 49, 359-367 (2013).
41. Simon C, et al A key role for EZH2 and associated genes in mouse and human adult T cell acute leukemia. Genes Dev. 26, 651-656 (2012).
42. Wu G, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251-253 (2012).
43. Lewis P. W, et al. Inhibition of PRC2 activity by a gain of function H3 mutation found in pediatric glioblastoma. Science. 340, 857-861 (2013).
44. Wang G. G, Cai L, Pasillas M. P, & Kamps M. P. NUP98 NSD1 links H3K36 methylation to Hox A gene activation and leukaemogenesis. Nat. Cell Biol. 9, 804-812 (2007).
45. Martinez-Garcia E, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4; 14) multiple myeloma cells. Blood. 117, 211-220 (2011).
46. Jaffe J. D, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386-1391 (2013).
47. Dalgliesh G. L, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 463, 360-363 (2010).
48. Gerlinger M, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
49. Hakimi A. A, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19, 3259-3267 (2013).
50. Mar B. G, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 5, 3469 (2014).
51. Rainier S, et al. Relaxation of imprinted genes in human cancer. Nature. 362, 747-749 (1993).
52. Ogawa O, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms tumour. Nature. 362, 749-751 (1993).
53. Zhan S, Shapiro D. N, & Helman L. J. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Invest. 94, 445-448 (1994).
54. Rainier S, Dobry C. J, & Feinberg A. P. Loss of imprinting in hepatoblastoma. Cancer Res. 55, 1836-1838 (1995).
55. Levine A. J, et al. Genetic variation in insulin pathway genes and distal colorectal adenoma risk. Int. J. Colorectal Dis. 27, 1587-1595 (2012).
56. Falls J. G, Pulford D. J, Wylie A. A, & Jirtle R. L. Genomic imprinting: implications for human disease. Am. J. Pathol. 154, 635-647 (1999).
57. Hassan A. B, & Howell J. A. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res. 60, 1070-1076 (2000).
58. Bjornsson H. T, et al. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J. Natl Cancer Inst. 99, 1270-1273 (2007).
59. Sakatani T, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 307, 1976-1978 (2005).
60. Shan J, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 56, 1004-1014 (2012).
61. DeBaun M. R, et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am. J. Hum. Genet. 70, 604-611 (2002).
62. Ferron S. R, et al. Differential genomic imprinting regulates paracrine and autocrine roles of IGF2 in mouse adult neurogenesis. Nat. Commun. 6, 8265 (2015).
63. Venkatraman A, et al. Maternal imprinting at the H19 Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature. 500, 345-349 (2013).
64. Ziegler A. N, et al. IGF II promotes stemness of neural restricted precursors. Stem Cells. 30, 1265-1276 (2012).
65. Wang L, et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor 1 receptor and ERBB2 receptor signaling. Blood. 110, 4111-4119 (2007).
66. Fischedick G, et al. Nanog induces hyperplasia without initiating tumors. Stem Cell Res. 13, 300-315 (2014).
67. Lengner C. J, et al. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell. 1, 403-415 (2007).
68. Marucci L, et al. Beta-catenin fluctuates in mouse ESCs and is essential for Nanog-mediated reprogramming of somatic cells to pluripotency. Cell Rep. 8, 1686-1696 (2014).
69. Doi A, et al. Differential methylation of tissue- And cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41, 1350-1353 (2009).
70. Lu X, Mazur S. J, Lin T, Appella E, & Xu Y. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene. 33, 2655-2664 (2014).
71. Ohnishi K, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell. 156, 663-677 (2014).
72. Hochedlinger K, Yamada Y, Beard C, & Jaenisch R. Ectopic expression of Oct 4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 121, 465-477 (2005).
73. Du J, Johnson L. M, Jacobsen S. E, & Patel D. J. DNA methylation pathways and their crosstalk with histone methylation. Nat. Rev. Mol. Cell Biol. 16, 519-532 (2015).
74. Wen B, Wu H, Shinkai Y, Irizarry R. A, & Feinberg A. P. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat. Genet. 41, 246-250 (2009).
75. Tonge P. D, et al. Divergent reprogramming routes lead to alternative stem-cell states. Nature. 516, 192-197 (2014).
76. Shakya A, et al. Pluripotency transcription factor Oct4 mediates stepwise nucleosome demethylation and depletion. Mol. Cell. Biol. 35, 1014-1025 (2015).
77. Gidekel S, Pizov G, Bergman Y, & Pikarsky E. Oct 3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell. 4, 361-370 (2003).
78. Lee B. K, et al. Tgif1 counterbalances the activity of core pluripotency factors in mouse embryonic stem cells. Cell Rep. 13, 52-60 (2015).
79. Rudin C. M, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111-1116 (2012).
80. Bass A. J, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242 (2009).
81. Luo W, et al. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS ONE. 8, e56324 (2013).
82. Chiou S. H, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70, 10433-10444 (2010).
83. Wang D, et al. Oct 4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 5, 10803-10815 (2014).
84. Boyer L. A, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 122, 947-956 (2005).
85. Visvader J. E. Cells of origin in cancer. Nature. 469, 314-322 (2011).
86. Friedmann-Morvinski D, & Verma I. M. Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep. 15, 244-253 (2014).
87. Medema J. P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 15, 338-344 (2013).
88. Kai K, et al. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci. 100, 2275-2282 (2009).
89. Gupta P. B, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 146, 633-644 (2011).
90. Schwitalla S, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 152, 25-38 (2013).
91. Friedmann-Morvinski D, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 338, 1080-1084 (2012).
92. Barker N, et al. Crypt stem cells as the cells of origin of intestinal cancer. Nature. 457, 608-611 (2009).
93. Jamieson C. H, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
94. Kikushige Y, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 20, 246-259 (2011).
95. Chen W. J, et al. Cancer-Associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 5, 3472 (2014).
96. Calabrese C, et al A perivascular niche for brain tumor stem cells. Cancer Cell. 11, 69-82 (2007).
97. Borovski T, et al. Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int. J. Cancer. 125, 1222-1230 (2009).
98. Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
99. Badeaux A. I, & Shi Y. Emerging roles for chromatin as a signal integration and storage platform. Nat. Rev. Mol. Cell Biol. 14, 211-224 (2013).
100. Kolybaba A, & Classen A. K. Sensing cellular states - signaling to chromatin pathways targeting Polycomb and Trithorax group function. Cell Tissue Res. 356, 477-493 (2014).
101. Wu B. K, & Brenner C. Suppression of TET1 dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 9, 1827-1840 (2014).
102. Gazin C, Wajapeyee N, Gobeil S, Virbasius C. M, & Green M. R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature. 449, 1073-1077 (2007).
103. Wajapeyee N, Malonia S. K, Palakurthy R. K, & Green M. R. Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev. 27, 2221-2226 (2013).
104. Serra R. W, Fang M, Park S. M, Hutchinson L, & Green M. R A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. eLife. 3, e02313 (2014).
105. Li H, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 460, 1136-1139 (2009).
106. Nguyen L. V, et al. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. Nature. 528, 267-271 (2015).
107. Trosko J. E, & Tai M. H. Adult stem cell theory of the multi-stage, multi-mechanism theory of carcinogenesis: role of inflammation on the promotion of initiated stem cells. Contrib. Microbiol. 13, 45-65 (2006).
108. Suman S, et al. Current perspectives of molecular pathways involved in chronic Inflammation-mediated breast cancer. Biochem. Biophys. Res. Commun. http://dx.doi.org/10.1016/j.bbrc.2015.10.133 (2015).
109. Barham W, et al. Aberrant activation of NF ?B signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer. 15, 647 (2015).
110. Iliopoulos D, Hirsch H. A, & Struhl K. An epigenetic switch involving NF ?B, Lin28, Let 7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 139, 693-706 (2009).
111. Levy D. E, & Darnell J. E. Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651-662 (2002).
112. Do D. V, et al A genetic and developmental pathway from STAT3 to the OCT4 NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev. 27, 1378-1390 (2013).
113. Yu H, Pardoll D, & Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer. 9, 798-809 (2009).
114. Tyagi N, et al. p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Cancer Lett. 370, 260-267 (2016).
115. Hutchins A. P, Diez D, & Miranda-Saavedra D. Genomic and computational approaches to dissect the mechanisms of STAT3s universal and cell type-specific functions. JAKSTAT. 2, e25097 (2013).
116. Abu-Remaileh M, et al. Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Res. 75, 2120-2130 (2015).
117. De Santa F, et al. The histone H3 lysine 27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell. 130, 1083-1094 (2007).
118. Lee J, et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell. 151, 547-558 (2012).
119. Taniguchi K, et al A gp130 Src-YAP module links inflammation to epithelial regeneration. Nature. 519, 57-62 (2015).
120. Strano S, et al. The transcriptional coactivator Yes-Associated protein drives p73 gene-Target specificity in response to DNA damage. Mol. Cell. 18, 447-459 (2005).
121. Bora-Singhal N, et al. YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells. 33, 1705-1718 (2015).
122. Zhu J, et al. Gain of function p53 mutants co opt chromatin pathways to drive cancer growth. Nature. 525, 206-211 (2015).
123. Pfister N. T, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 29, 1298-1315 (2015).
124. Rai K, et al. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell. 142, 930-942 (2010).
125. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483, 474-478 (2012).
126. Xiao M, et al. Inhibition of a KG dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326-1338 (2012).
127. Vogelstein B, et al. Cancer genome landscapes. Science. 339, 1546-1558 (2013).
128. Heyn H, et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl Acad. Sci. USA. 109, 10522-10527 (2012).
129. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013).
130. Florath I, Butterbach K, Muller H, Bewerunge- Hudler M, & Brenner H. Cross-sectional and longitudinal changes in DNA methylation with age: an epigenome-wide analysis revealing over 60 novel age-Associated CpG sites. Hum. Mol. Genet. 23, 1186-1201 (2014).
131. Yuan T, et al. An integrative multi-scale analysis of the dynamic DNA methylation landscape in aging. PLoS Genet. 11, e1004996 (2015).
132. Teschendorff A. E, West J, & Beck S. Age-Associated epigenetic drift: implications, and a case of epigenetic thrift?. Hum. Mol. Genet. 22, R7-R15 (2013).
133. Sun D, et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell. 14, 673-688 (2014).
134. Benayoun B. A, Pollina E. A, & Brunet A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat. Rev. Mol. Cell Biol. 16, 593-610 (2015).
135. Siebold A. P, et al. Polycomb Repressive Complex 2 and Trithorax modulate Drosophila longevity and stress resistance. Proc. Natl Acad. Sci. USA. 107, 169-174 (2010).
136. Greer E. L, et al. Members of the H3K4 trimethylation complex regulate lifespan in a germline-dependent manner in C elegans. Nature. 466, 383-387 (2010).
137. Zhang W, et al. Aging stem cells A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science. 348, 1160-1163 (2015).
138. McCord R. P, et al. Correlated alterations in genome organization, histone methylation, and DNA-lamin A/C interactions in Hutchinson-Gilford progeria syndrome. Genome Res. 23, 260-269 (2013).
139. Riedel C. G, et al. DAF 16 employs the chromatin remodeller SWI/SNF to promote stress resistance and longevity. Nat. Cell Biol. 15, 491-501 (2013).
140. Mihaylova M. M, et al. Class IIa histone deacetylases are hormone-Activated regulators of FOXO and mammalian glucose homeostasis. Cell. 145, 607-621 (2011).
141. Bungard D, et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science. 329, 1201-1205 (2010).
142. Wilson M. J, Shivapurkar N, & Poirier L. A. Hypomethylation of hepatic nuclear DNA in rats fed with a carcinogenic methyl-deficient diet. Biochem. J. 218, 987-990 (1984).
143. Ghoshal A. K, & Farber E. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens. Carcinogenesis. 5, 1367-1370 (1984).
144. Bhave M. R, Wilson M. J, & Poirier L. A. c H ras and c K ras gene hypomethylation in the livers and hepatomas of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis. 9, 343-348 (1988).
145. Pogribny I. P, et al. Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res. 55, 1894-1901 (1995).
146. Giovannucci E, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J. Natl Cancer Inst. 85, 875-884 (1993).
147. Ciappio E. D, Mason J. B, & Crott J. W. Maternal one-carbon nutrient intake and cancer risk in offspring. Nutr. Rev. 69, 561-571 (2011).
148. Choi S. W, et al. Chronic alcohol consumption induces genomic but not p53 specific DNA hypomethylation in rat colon. J. Nutr. 129, 1945-1950 (1999).
149. van Engeland M, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 63, 3133-3137 (2003).
150. Cortessis V. K, et al. Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. Hum. Genet. 131, 1565-1589 (2012).
151. Zochbauer-Muller S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int. J. Cancer. 107, 612-616 (2003).
152. Russo A. L, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin. Cancer Res. 11, 2466-2470 (2005).
153. Bollati V, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 67, 876-880 (2007).
154. Maekita T, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 12, 989-995 (2006).
155. Chan A. O, et al. Eradication of Helicobacter pylori infection reverses E cadherin promoter hypermethylation. Gut. 55, 463-468 (2006).
156. Christensen B. C, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 69, 227-234 (2009).
157. Pujadas E, & Feinberg A. P. Regulated noise in the epigenetic landscape of development and disease. Cell. 148, 1123-1131 (2012).
158. Hansen K. D, et al. Large-scale hypomethylated blocks associated with Epstein-Barr virus-induced B cell immortalization. Genome Res. 24, 177-184 (2014).
159. Meuleman W, et al. Constitutive nuclear lamina-genome interactions are highly conserved and associated with A/T rich sequence. Genome Res. 23, 270-280 (2013).
160. Banerji C. R, et al. Cellular network entropy as the energy potential in Waddingtons differentiation landscape. Sci. Rep. 3, 3039 (2013).
161. Chen X, et al. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev. 26, 2499-2511 (2012).
162. Liu N, et al. Recognition of H3K9 methylation by GLP is required for efficient establishment of H3K9 methylation, rapid target gene repression, and mouse viability. Genes Dev. 29, 379-393 (2015).
163. Ahmed K, et al. Global chromatin architecture reflects pluripotency and lineage commitment in the early mouse embryo. PLoS One. 5, e10531 (2010).
164. Therizols P, et al. Chromatin decondensation is sufficient to alter nuclear organization in embryonic stem cells. Science. 346, 1238-1242 (2014).
165. Eskeland R, et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol. Cell. 38, 452-464 (2010).
166. Vallot C, Herault A, Boyle S, Bickmore W. A, & Radvanyi F. PRC2 independent chromatin compaction and transcriptional repression in cancer. Oncogene. 34, 741-751 (2015).
167. Lemaitre C, & Bickmore W. A. Chromatin at the nuclear periphery and the regulation of genome functions. Histochem. Cell Biol. 144, 111-122 (2015).
168. Burke B, & Stewart C. L. The nuclear lamins: flexibility in function. Nat. Rev. Mol. Cell Biol. 14, 13-24 (2013).
169. Shah P. P, et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev. 27, 1787-1799 (2013).
170. Harr J. C, et al. Directed targeting of chromatin to the nuclear lamina is mediated by chromatin state and A type lamins. J. Cell Biol. 208, 33-52 (2015).
171. Towbin B. D, et al. Step-wise methylation of histone H3K9 positions heterochromatin at the nuclear periphery. Cell. 150, 934-947 (2012).
172. Guarda A, Bolognese F, Bonapace I. M, & Badaracco G. Interaction between the inner nuclear membrane lamin B receptor and the heterochromatic methyl binding protein, MeCP2. Exp. Cell Res. 315, 1895-1903 (2009).
173. Schooley A, Moreno-Andres D, De Magistris P, Vollmer B, & Antonin W. The lysine demethylase LSD1 is required for nuclear envelope formation at the end of mitosis. J. Cell Sci. 128, 3466-3477 (2015).
174. Montes de Oca R, Shoemaker C. J, Gucek M, Cole R. N, & Wilson K. L. Barrier-To autointegration factor proteome reveals chromatin-regulatory partners. PLoS One. 4, e7050 (2009).
175. Demmerle J, Koch A. J, & Holaska J. M. The nuclear envelope protein emerin binds directly to histone deacetylase 3 (HDAC3) and activates HDAC3 activity. J. Biol. Chem. 287, 22080-22088 (2012).
176. Somech R, et al. The nuclear-envelope protein and transcriptional repressor LAP2β interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation. J. Cell Sci. 118, 4017-4025 (2005).
177. Holaska J. M, & Wilson K. L. An emerin proteome: purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechanosensing, and nuclear architecture. Biochemistry. 46, 8897-8908 (2007).
178. Finlan L. E, et al. Recruitment to the nuclear periphery can alter expression of genes in human cells. PLoS Genet. 4, e1000039 (2008).
179. Melcer S, et al. Histone modifications and lamin A regulate chromatin protein dynamics in early embryonic stem cell differentiation. Nat. Commun. 3, 910 (2012).
180. Adamo A, et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat. Cell Biol. 13, 652-659 (2011).
181. Ma D. K, Chiang C. H, Ponnusamy K, Ming G. L, & Song H. G9a and Jhdm2a regulate embryonic stem cell fusion-induced reprogramming of adult neural stem cells. Stem Cells. 26, 2131-2141 (2008).
182. Sadaie M, et al. Redistribution of the Lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence. Genes Dev. 27, 1800-1808 (2013).
183. Zane L, Sharma V, & Misteli T. Common features of chromatin in aging and cancer: cause or coincidence?. Trends Cell Biol. 24, 686-694 (2014).
184. Shankar S. R, et al. G9a, a multipotent regulator of gene expression. Epigenetics. 8, 16-22 (2013).
185. McDonald O. G, Wu H, Timp W, Doi A, & Feinberg A. P. Genome-scale epigenetic reprogramming during epithelial-To mesenchymal transition. Nat. Struct. Mol. Biol. 18, 867-874 (2011).
186. Mani S. A, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133, 704-715 (2008).
187. Feinberg A. P, & Irizarry R. A. Evolution in health and medicine Sackler colloquium: stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc. Natl Acad. Sci. USA 107 (Suppl. 1), 1757-1764 (2010).
188. Timp W, & Feinberg A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer. 13, 497-510 (2013).
189. Ohlsson R, et al. Epigenetic variability and the evolution of human cancer. Adv. Cancer Res. 88, 145-168 (2003).
190. Hansen K. D, et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768-775 (2011).
191. Timp W, et al. Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors. Genome Med. 6, 61 (2014).
192. Berman B. P, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-Associated domains. Nat. Genet. 44, 40-46 (2012).
193. Teschendorff A. E, et al. Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med. 4, 24 (2012).
194. Teschendorff A. E, & Widschwendter M. Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics. 28, 1487-1494 (2012).
195. Dinalankara W, & Bravo H. C. Gene expression signatures based on variability can robustly predict tumor progression and prognosis. Cancer Inform. 14, 71-81 (2015).
196. Vandiver A. R, et al. Age and sun exposure-related widespread genomic blocks of hypomethylation in nonmalignant skin. Genome Biol. 16, 80 (2015).
197. Teschendorff A. E, Banerji C. R, Severini S, Kuehn R, & Sollich P. Increased signaling entropy in cancer requires the scale-free property of protein interaction networks. Sci. Rep. 5, 9646 (2015).
198. Kumar R. M, et al. Deconstructing transcriptional heterogeneity in pluripotent stem cells. Nature. 516, 56-61 (2014).
199. Singer Z. S, et al. Dynamic heterogeneity and DNA methylation in embryonic stem cells. Mol. Cell. 55, 319-331 (2014).
200. Landan G, et al. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat. Genet. 44, 1207-1214 (2012).
201. Reddy K. L, & Feinberg A. P. Higher order chromatin organization in cancer. Semin. Cancer Biol. 23, 109-115 (2013).
202. Carone D. M, & Lawrence J. B. Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery. Semin. Cancer Biol. 23, 99-108 (2013).
203. Kind J, et al. Single-cell dynamics of genome-nuclear lamina interactions. Cell. 153, 178-192 (2013).
204. Schlimgen R. J, Reddy K. L, Singh H, & Krangel M. S. Initiation of allelic exclusion by stochastic interaction of Tcrb alleles with repressive nuclear compartments. Nat. Immunol. 9, 802-809 (2008).
205. Zhao H, et al. PARP1- And CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription. Mol. Cell. 59, 984-997 (2015).
206. Wassef M, et al. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev. 29, 2547-2562 (2015).
207. Guelen L, et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature. 453, 948-951 (2008).
208. Boros J, Arnoult N, Stroobant V, Collet J. F, & Decottignies A. Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1alpha at chromatin. Mol. Cell. Biol. 34, 3662-3674 (2014).
209. Hnisz D, et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell. 58, 362-370 (2015).
210. Bahar Halpern K, et al. Bursty gene expression in the intact mammalian liver. Mol. Cell. 58, 147-156 (2015).
211. Lam A, & Deans T. L A noisy tug of war: the battle between transcript production and degradation in the liver. Dev. Cell. 33, 3-4 (2015).
212. Li G, et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell. 148, 84-98 (2012).
213. Noordermeer D, et al. Variegated gene expression caused by cell-specific long-range DNA interactions. Nat. Cell Biol. 13, 944-951 (2011).
214. Whyte W. A, et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature. 482, 221-225 (2012).
215. Loven J, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 153, 320-334 (2013).
216. Dey A, Nishiyama A, Karpova T, McNally J, & Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell. 20, 4899-4909 (2009).
217. Adam R. C, et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature. 521, 366-370 (2015).
218. Gomez-Diaz E, & Corces V. G. Architectural proteins: regulators of 3D genome organization in cell fate. Trends Cell Biol. 24, 703-711 (2014).
219. Lupianez D. G, et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell. 161, 1012-1025 (2015).
220. Kanduri C, et al. Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr. Biol. 10, 853-856 (2000).
221. Gerlinger M, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
222. Yildirim E, Sadreyev R. I, Pinter S. F, & Lee J. T. X chromosome hyperactivation in mammals via nonlinear relationships between chromatin states and transcription. Nat. Struct. Mol. Biol. 19, 56-61 (2012).
223. Stephens A. D, et al. Pericentric chromatin loops function as a nonlinear spring in mitotic force balance. J. Cell Biol. 200, 757-772 (2013).
224. Pang B, de Jong J, Qiao X, Wessels L. F, & Neefjes J. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat. Chem. Biol. 11, 472-480 (2015).
225. Cheng J, et al. Tryptophan derivatives regulate the transcription of Oct4 in stem-like cancer cells. Nat. Commun. 6, 7209 (2015).
226. Love C, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44, 1321-1325 (2012).
227. Imielinski M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150, 1107-1120 (2012).
228. Robinson G, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 488, 43-48 (2012).
229. Fujimoto A, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012).
230. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487, 330-337 (2012).
231. Li M, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011).
232. Hodis E, et al A landscape of driver mutations in melanoma. Cell. 150, 251-263 (2012).
233. Biankin A. V, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 491, 399-405 (2012).
234. Stephens P. J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 486, 400-404 (2012).
235. Smith M. J, et al. Loss of function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat. Genet. 45, 295-298 (2013).
236. Jiao Y, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 331, 1199-1203 (2011).
237. Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 482, 226-231 (2012).
238. Kolla V, Zhuang T, Higashi M, Naraparaju K, & Brodeur G. M. Role of CHD5 in human cancers: 10 years later. Cancer Res. 74, 652-658 (2014).
239. Puente X. S, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 526, 519-524 (2015).
240. Berger M. F, et al. The genomic complexity of primary human prostate cancer. Nature. 470, 214-220 (2011).
241. Tahara T, et al. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology. 146, 530-538 e5 (2014).
242. Gui Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875-878 (2011).
243. Le Gallo M, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat. Genet. 44, 1310-1315 (2012).
244. Neumann M, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 121, 4749-4752 (2013).
245. Kanai Y, Ushijima S, Nakanishi Y, Sakamoto M, & Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett. 192, 75-82 (2003).
246. Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289-2301 (2009).
247. Scourzic L, Mouly E, & Bernard O. A. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 7, 9 (2015).
248. Krauthammer M, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
249. Pasqualucci L, et al. Inactivating mutations of acetyltransferase genes in B cell lymphoma. Nature. 471, 189-195 (2011).
250. Peifer M, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012).
251. Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321, 1801-1806 (2008).
252. Ward R, Johnson M, Shridhar V, van Deursen J, & Couch F. J. CBP truncating mutations in ovarian cancer. J. Med. Genet. 42, 514-518 (2005).
253. Mullighan C. G, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 471, 235-239 (2011).
254. Ropero S, et al A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38, 566-569 (2006).
255. Hanigan C. L, et Al. An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1. Gastroenterology. 135, 1654-1664 (2008).
256. Sjoblom T, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 314, 268-274 (2006).
257. Thirman M. J, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med. 329, 909-914 (1993).
258. Krivtsov A. V, & Armstrong S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer. 7, 823-833 (2007).
259. Rao R. C, & Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat. Rev. Cancer. 15, 334-346 (2015).
260. Kandoth C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 502, 333-339 (2013).
261. Zang Z. J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012).
262. Zhang J, et al. The genetic basis of early T cell precursor acute lymphoblastic leukaemia. Nature. 481, 157-163 (2012).
263. Vougiouklakis T, Hamamoto R, Nakamura Y, & Saloura V. The NSD family of protein methyltransferases in human cancer. Epigenomics. 7, 863-874 (2015).
264. Fontebasso A. M, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 125, 659-669 (2013).
265. van Haaften G, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
266. Grasso C. S, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487, 239-243 (2012).
267. Van Vlierberghe P, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 25, 130-134 (2011).
268. Van Vlierberghe P, et al. PHF6 mutations in T cell acute lymphoblastic leukemia. Nat. Genet. 42, 338-342 (2010).
269. Huether R, et al. The landscape of somatic mutations in epigenetic regulators across 1, 000 paediatric cancer genomes. Nat. Commun. 5, 3630 (2014).
270. Wang G. G, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 459, 847-851 (2009).
271. French C. A, et al. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15; 19). Am. J. Pathol. 159, 1987-1992 (2001).
272. Pena P. V, et al. Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor. J. Mol. Biol. 380, 303-312 (2008).
273. Behjati S, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat. Genet. 45, 1479-1482 (2013).
274. Li H, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 123, 1487-1498 (2014).